Fundraising FoxAvalon BioVentures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)inJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatJay B. Lichter· per SEC Form D
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalPappas CapitalPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers.
BiotechHealthtechLa Jolla, US
Ahmet Tutuncu(CEO and Co-founder)inAhmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)
BoardTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)
Co-investorsAlexandriaCorrelation Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.